Market By Products, Applications, Diseases And Geography | Forecast 2019-2027
The detailed analysis by Triton anticipated that the global human microbiome market, in terms of revenue, is expected to display an upward trend and estimated to grow at a CAGR of 21.89% for forecasting period of 2019-2027. The market was assessed to be worth $253.8 million in the year 2018 and is predicted to generate a revenue of approximately $1236.7 million by the year 2027.
Report scope can be customized per your requirements. Request For Customization
The human microbiota includes 10-100 trillion related microbial cells sheltered and possessed by the human body, chiefly bacteria inside the gut. The microbiome of a human includes information about the genes of these cells. Globally, microbiome projects have been initiated to understand the roles played by these symbionts and their influences on human healthiness. Joshua Lederberg coined the term 'Human Microbiome' in 2001. Although bacteria are the most significant part of the human microbiome, the human body also hosts single-celled organisms which are referred as archaea, along with fungi, viruses and other microbes such as viruses that attack the bacteria. Collectively, these are known as the human microbiota. Often, the two terms are used interchangeably. The term “microbiota” can be defined as the bacterial taxa related to humans, and the term ‘microbiome’ can be defined as the collection of these microbes, and it’s genes.
Also, the term “metagenomics” is often referred to as a classification of total DNA. However, now it is being applied rapidly to studies related to indicator genes, namely the 16S rRNA gene. However, many new inventions are leading us to query the notions that are important for forming the description of the human microbiome, such as the definition of the Operational Taxonomic Units (OTUs) that make up the microbiota. Other concepts questioned include the stability of an individual's microbiome and whether a person has one form of microbiome or multiple. Microbiome-based treatment and diagnosis methods have been proving to be quite promising, thus conquering the confidence of the investors in the market.
Within this report, the key insights regarding the industry are discussed. Also, Porter’s five force analysis, the regulatory framework, supply chain outlook, key buying outlook, estimate outlook, strategies in product development, parent market outlook and pipeline products are studied for the human microbiome industry.
Market drivers like precision medicines leading to increased adoption of human microbiomes, the increasing pervasiveness of chronic diseases and emphasis on early disease diagnosis are analyzed. The industry is facing market restraints like lack of technological expertise, barriers in the initial analysis, lack of skilled professionals and stringent government protocols, which are obstructing the industry growth. Key opportunities like increasing R&D investments in the microbiome, high funding for developing new drugs and changing lifestyle in the developing countries can be leveraged by the industry to get towards the projected growth. The sector faces challenges such as lack of awareness at this moment.
To get detailed insights on segments, Download Sample Report
Geographies covered for human microbiome market are:
o North America: the United States and Canada
o Europe: United Kingdom, Germany, France, Italy, Spain, Russia and Rest of Europe
o Asia-Pacific: China, Japan, India, South Korea, ASEAN countries, Australia & New Zealand and Rest of Asia Pacific
o Latin America: Brazil, Mexico and Rest of Latin America
o The Middle East and Africa: United Arab Emirates, Turkey, Saudi Arabia, South Africa and Rest of the Middle East and Africa
The human microbiome market report is segmented as follows:
• By products:
o Probiotics
o Foods
o Prebiotics
o Medical food
o Diagnostic devices
o Drugs
o Other products
• By applications:
o Drugs
o Diagnostics
• By diseases:
o Cancer
o Obesity
o Ulcerative colitis
o Crohn’s disease
o C. Difficle infection
o Lactose intolerance
o Dental caries
o Type 2 diabetes
o Recurrent bacterial vaginosis and UTI
o Hyperoxaluria
o Urea cycle disorder
o Hepatic Encephalopathy
o Celiac disease
o Phenylketonuria
o Non-alcoholic steatohepatitis
The key players engaged in the human microbiome market are 4D Pharma, Metabiomics, Avidbiotics Inc., Microbiome Therapeutics, Actogenix NV, Metabogen AB, Avidbiotics Corp., Miomics, Enterome SA and Osel Inc.
The strategic analysis for each of these companies in the human microbiome market is covered in detail. Company market share helps to dive into the information about the key market players in this industry and how much hold they have on the market. With an aim to enhance their market strategies, companies are looking to collaborate with eminent researchers, physicians, and scientists in the human microbiome field.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. GLOBAL
HUMAN MICROBIOME MARKET- SUMMARY
2. INDUSTRY
OUTLOOK
2.1. PORTER’S
FIVE FORCES OUTLOOK
2.1.1. THREAT
OF NEW ENTRANTS
2.1.2. THREAT
OF SUBSTITUTE PRODUCTS OR SERVICES
2.1.3. BARGAINING
POWER OF BUYER
2.1.4. BARGAINING
POWER OF SUPPLIER
2.1.5. INTENSITY
OF COMPETITIVE RIVALRY
2.2. KEY
INSIGHTS
2.3. REGULATORY
FRAMEWORK
2.4. SUPPLY
CHAIN OUTLOOK
2.5. KEY
BUYING OUTLOOK
2.6. ESTIMATE
OUTLOOK
2.7. STRATEGIES
IN PRODUCT DEVELOPMENT
2.8. PARENT
MARKET OUTLOOK
2.9. MARKET
SHARE OUTLOOK
2.10.
PIPELINE PRODUCTS
2.11.
MARKET DRIVERS
2.11.1.
PRECISION MEDICINES ARE
INCREASING THE ADOPTION OF HUMAN MICROBIOMES
2.11.2.
RISING PERVASIVENESS OF
CHRONIC DISEASES
2.11.3.
EMPHASIS ON EARLY DISEASE
DIAGNOSIS
2.12.
MARKET RESTRAINTS
2.12.1.
LACK OF TECHNOLOGICAL EXPERTISE
2.12.2.
BARRIERS IN INITIAL ANALYSIS
2.12.3.
LACK OF SKILLED PROFESSIONALS
2.12.4.
STRINGENT GOVERNMENT PROTOCOLS
2.13.
MARKET OPPORTUNITIES
2.13.1.
INCREASING R&D INVESTMENTS
IN MICROBIOME
2.13.2.
SWELLING INVESTMENT IN NEW
DRUGS
2.13.3.
CHANGING LIFESTYLES IN
DEVELOPED COUNTRIES
2.14.
MARKET CHALLENGES
2.14.1.
LACK OF AWARENESS
3. HUMAN
MICROBIOME INDUSTRY OUTLOOK - BY PRODUCTS
3.1. PROBIOTICS
3.2. FOODS
3.3. PREBIOTICS
3.4. MEDICAL
FOODS
3.5. DIAGNOSTIC
DEVICE
3.6. DRUGS
3.7. OTHER
PRODUCTS
4. HUMAN
MICROBIOME INDUSTRY OUTLOOK - BY APPLICATIONS
4.1. DRUGS
4.2. DIAGNOSTICS
5. HUMAN
MICROBIOME INDUSTRY OUTLOOK - BY DISEASES
5.1. CANCER
5.2. OBESITY
5.3. ULCERATIVE
COLITIS
5.4. CROHN’S
DISEASE
5.5. C.
DIFFICLE INFECTION
5.6. LACTOSE
INTOLERANCE
5.7. DENTAL
CARIES
5.8. TYPE
2 DIABETES
5.9. RECURRENT
BACTERIAL VAGINOSIS AND UTI
5.10.
SKIN DISORDERS
5.11.
HYPEROXALURIA
5.12.
UREA CYCLE DISORDER
5.13.
HEPATIC ENCEPHALOPATHY
5.14.
CELIAC DISEASE
5.15.
PHENYLKETONURIA
5.16.
NON-ALCOHOLIC STEATOHEPATITIS
6. HUMAN
MICROBIOME INDUSTRY – REGIONAL OUTLOOK
6.1. NORTH
AMERICA
6.1.1. COUNTRY
ANALYSIS
6.1.1.1. THE
UNITED STATES
6.1.1.2. CANADA
6.2. EUROPE
6.2.1. COUNTRY
ANALYSIS
6.2.1.1. THE
UNITED KINGDOM
6.2.1.2. FRANCE
6.2.1.3. GERMANY
6.2.1.4. ITALY
6.2.1.5. SPAIN
6.2.1.6. RUSSIA
6.2.1.7. REST
OF EUROPE
6.3. ASIA
PACIFIC
6.3.1. COUNTRY
ANALYSIS
6.3.1.1. CHINA
6.3.1.2. INDIA
6.3.1.3. JAPAN
6.3.1.4. SOUTH
KOREA
6.3.1.5. AUSTRALIA
& NEW ZEALAND
6.3.1.6. ASEAN
COUNTRIES
6.3.1.7. REST
OF APAC
6.4. LATIN
AMERICA
6.4.1. COUNTRY
ANALYSIS
6.4.1.1. BRAZIL
6.4.1.2. MEXICO
6.4.1.3. REST
OF LATIN AMERICA
6.5. MIDDLE
EAST & AFRICA
6.5.1. COUNTRY
ANALYSIS
6.5.1.1. SAUDI
ARABIA
6.5.1.2. TURKEY
6.5.1.3. UNITED
ARAB EMIRATES
6.5.1.4. SOUTH
AFRICA
6.5.1.5. REST
OF MIDDLE EAST AND AFRICA
7. COMPETITIVE
LANDSCAPE
7.1. 4D
PHARMA
7.2. AVIDBIOTICS
INC.
7.3. ACTOGENIX
N.V. (ACQUIRED BY INTREXON CORPORATION)
7.4. AVIDBIOTICS
CORP.
7.5. ENTEROME
SA
7.6. METABIOMICS
7.7. MICROBIOME
THERAPEUTICS
7.8. METABOGEN
AB
7.9. MIOMICS
7.10.
OSEL INC.
7.11.
REBIOTIX
7.12.
RITTER PHARMACEUTICALS, INC.
7.13.
SECOND GENOME
7.14.
SYMBERIX INC.
7.15.
SYMBIOTIX
BIOTHERAPIES, INC.
7.16.
VEDANTA BIOSCIENCES, INC. (ACQUIRED BY PURETECH HEALTH PLC)
8. METHODOLOGY
& SCOPE
8.1. RESEARCH
SCOPE
8.2. SOURCES
OF DATA
RESEARCH METHODOLOGY
TABLE 1 GLOBAL
HUMAN MICROBIOME MARKET BY GEOGRAPHY 2019-2023 ($ MILLION)
TABLE 2 GLOBAL
HUMAN MICROBIOME MARKET BY GEOGRAPHY 2023-2027 ($ MILLION)
TABLE 3 INVESTMENTS
IN MICROBIOLOGY
TABLE 4 MICROBIOME
DRUG DEVELOPMENT APPROACHES
TABLE 5 INCIDENCE
OF DIABETES IN THE MAJOR COUNTRIES IN 2016( MILLIONS)
TABLE 6 COMPANIES
WORKING TOWARDS DEVELOPING NEW DRUGS
TABLE 7 GLOBAL
HUMAN MICROBIOME MARKET BY APPLICATIONS 2019-2023 ($ MILLION)
TABLE 8 GLOBAL
HUMAN MICROBIOME MARKET BY APPLICATIONS 2023-2027 ($ MILLION)
TABLE 9 GLOBAL
HUMAN MICROBIOME MARKET BY PRODUCTS 2019-2023 ($ MILLION)
TABLE 10 GLOBAL
HUMAN MICROBIOME MARKET BY PRODUCTS 2023-2027 ($ MILLION)
TABLE 11 GLOBAL
HUMAN MICROBIOME MARKET BY DISEASES 2019-2023 ($ MILLION)
TABLE 12 GLOBAL
HUMAN MICROBIOME MARKET BY DISEASES 2023-2027 ($ MILLION)
TABLE 13 MICROBIOTA
ASSOCIATED WITH CANCERS
TABLE 14 MICROBIOME-BASED
DRUGS IN DEVELOPMENT FOR CANCER
TABLE 15 MICROBIOTA
ASSOCIATED WITH OBESITY
TABLE 16 MICROBIOME-BASED
DRUGS IN DEVELOPMENT FOR OBESITY
TABLE 17 MICROBIOTA
ASSOCIATED WITH TYPE 2 DIABETES
TABLE 18 MICROBIOME-BASED
DRUGS IN DEVELOPMENT FOR TYPE 2 DIABETES
TABLE 19 MICROBIOME-BASED
DRUGS IN DEVELOPMENT FOR ULCERATIVE COLITIS
TABLE 20 MICROBIOME-BASED
DRUGS IN DEVELOPMENT FOR CROHN’S DISEASE
TABLE 21 MICROBIOME-BASED
DRUGS IN DEVELOPMENT FOR CLOSTRIDIUM DIFFICLE INFECTION
TABLE 22 MICROBIOME-BASED
DRUGS IN DEVELOPMENT FOR CLOSTRIDIUM DIFFICLE INFECTION
TABLE 23 MICROBIOME-BASED
DRUGS IN DEVELOPMENT FOR CLOSTRIDIUM DIFFICLE INFECTION
TABLE 24 MICROBIOME-BASED
DRUGS IN DEVELOPMENT FOR RECURRENT BACTERIAL VAGINOSIS AND URINARY TRACT
INFECTION
TABLE 25 MICROBIOME-BASED
DRUGS IN DEVELOPMENT FOR SKIN DISEASES
TABLE 26 MICROBIOME-BASED
DRUGS IN DEVELOPMENT FOR SKIN DISEASES
TABLE 27 MICROBIOTA
ASSOCIATED WITH CELIAC DISEASE
TABLE 28 MICROBIOME-BASED
DRUGS IN DEVELOPMENT FOR CELIAC DISEASE
TABLE 29 MICROBIOME-BASED
DRUGS IN DEVELOPMENT FOR UREA CYCLE DISORDER
TABLE 30 MICROBIOME-BASED
DRUGS IN DEVELOPMENT FOR NON-ALCOHOLIC STEATOHEPATITIS
TABLE 31 MICROBIOME-BASED
DRUGS IN DEVELOPMENT FOR HEPATIC ENCEPHALOPATHY
TABLE 32 GLOBAL
HUMAN MICROBIOME MARKET BY GEOGRAPHY 2019-2023 ($ MILLION)
TABLE 33 GLOBAL
HUMAN MICROBIOME MARKET BY GEOGRAPHY 2023-2027 ($ MILLION)
TABLE 34 NORTH
AMERICA HUMAN MICROBIOME MARKET 2019-2023 ($ MILLION)
TABLE 35 NORTH
AMERICA HUMAN MICROBIOME MARKET 2023-2027 ($ MILLION)
TABLE 36 COLLECTIVE
PROGRAMS BY CIHR'S ON HUMAN MICROBIOME IN 2017
TABLE 37 EUROPE
HUMAN MICROBIOME MARKET 2019-2023 ($ MILLION)
TABLE 38 EUROPE
HUMAN MICROBIOME MARKET 2012-2026 ($ MILLION)
TABLE 39 ASIA
PACIFIC HUMAN MICROBIOME MARKET 2019-2023 ($ MILLION)
TABLE 40 ASIA
PACIFIC HUMAN MICROBIOME MARKET 2023-2027 ($ MILLION)
TABLE 41 LATIN
AMERICA HUMAN MICROBIOME MARKET 2019-2023 ($ MILLION)
TABLE 42 LATIN
AMERICA HUMAN MICROBIOME MARKET 2023-2027 ($ MILLION)
TABLE 43 MIDDLE
EAST AND AFRICA HUMAN MICROBIOME MARKET 2019-2023 ($ MILLION)
TABLE 44 MIDDLE
EAST AND AFRICA HUMAN MICROBIOME MARKET 2023-2027 ($ MILLION)
FIGURE 1 GLOBAL HUMAN MICROBIOME MARKET 2019-2027
($ MILLION)
FIGURE 2 HEALTHCARE EXPENDITURE IN THE U.S.
2015-2025 (% OF GDP)
FIGURE 3 RESEARCH AND DEVELOPMENT SPENDING IN THE
LIFE SCIENCE 2014-2016 ($ BILLION)
FIGURE 4 ESTIMATED NUMBER OF PEOPLE WITH CHRONIC
CONDITIONS IN UNITED STATES
FIGURE 5 GLOBAL HUMAN MICROBIOME MARKET IN DRUGS
2019-2027 ($ MILLION)
FIGURE 6 GLOBAL HUMAN MICROBIOME MARKET IN DIAGNOSTIC
DEVICE 2019-2027 ($ MILLION)
FIGURE 7 GLOBAL HUMAN MICROBIOME MARKET IN
PROBIOTICS 2019-2027 ($ MILLION)
FIGURE 8 GLOBAL HUMAN MICROBIOME MARKET IN FOODS
2019-2027 ($ MILLION)
FIGURE 9 GLOBAL HUMAN MICROBIOME MARKET IN
PREBIOTICS 2019-2027 ($ MILLION)
FIGURE 10 GLOBAL HUMAN MICROBIOME MARKET IN MEDICAL
FOODS 2019-2027 ($ MILLION)
FIGURE 11 GLOBAL HUMAN MICROBIOME MARKET IN DIAGNOSTIC
DEVICE 2019-2027 ($ MILLION)
FIGURE 12 GLOBAL HUMAN MICROBIOME MARKET IN DRUGS
2019-2027 ($ MILLION)
FIGURE 13 GLOBAL HUMAN MICROBIOME MARKET IN OTHER
PRODUCTS 2019-2027 ($ MILLION)
FIGURE 14 GLOBAL HUMAN MICROBIOME MARKET IN CANCER
2019-2027 ($ MILLION)
FIGURE 15 GLOBAL HUMAN MICROBIOME MARKET IN OBESITY
2019-2027 ($ MILLION)
FIGURE 16 GLOBAL HUMAN MICROBIOME MARKET IN TYPE 2
DIABETES 2019-2027 ($ MILLION)
FIGURE 17 GLOBAL HUMAN MICROBIOME MARKET IN ULCERATIVE
COLITIS 2019-2027 ($ MILLION)
FIGURE 18 GLOBAL HUMAN MICROBIOME MARKET IN CROHN’S
DISEASE 2019-2027 ($ MILLION)
FIGURE 19 GLOBAL HUMAN MICROBIOME MARKET IN C. DIFFICLE
INFECTION 2019-2027 ($ MILLION)
FIGURE 20 GLOBAL HUMAN MICROBIOME MARKET IN LACTOSE
INTOLERANCE 2019-2027 ($ MILLION)
FIGURE 21 GLOBAL HUMAN MICROBIOME MARKET IN DENTAL
CARIES 2019-2027 ($ MILLION)
FIGURE 22 GLOBAL HUMAN MICROBIOME MARKET IN RECURRENT
BACTERIAL VAGINOSIS AND UTI 2019-2027 ($ MILLION)
FIGURE 23 GLOBAL HUMAN MICROBIOME MARKET IN SKIN
DISORDERS 2019-2027 ($ MILLION)
FIGURE 24 MICROBES INVOLVED IN HEALTHY FACIAL SKIN
(PERCENT MICROBES)
FIGURE 25 GLOBAL HUMAN MICROBIOME MARKET IN
HYPEROXALURIA 2019-2027 ($ MILLION)
FIGURE 26 GLOBAL HUMAN MICROBIOME MARKET IN CELIAC
DISEASE 2019-2027 ($ MILLION)
FIGURE 27 GLOBAL HUMAN MICROBIOME MARKET IN UREA CYCLE
DISORDER 2019-2027 ($ MILLION)
FIGURE 28 GLOBAL HUMAN MICROBIOME MARKET IN
PHENYLKETONURIA 2019-2027 ($ MILLION)
FIGURE 29 GLOBAL HUMAN MICROBIOME MARKET IN
NON-ALCOHOLIC STEATOHEPATITIS 2019-2027 ($ MILLION)
FIGURE 30 GLOBAL HUMAN MICROBIOME MARKET IN HEPATIC
ENCEPHALOPATHY 2019-2027 ($ MILLION)
FIGURE 31 NORTH AMERICA HUMAN MICROBIOME MARKET
2019-2027 ($ MILLION)
FIGURE 32 THE U.S. HUMAN MICROBIOME MARKET 2019-2027 ($
MILLION)
FIGURE 33 CANADA HUMAN MICROBIOME MARKET 2019-2027 ($
MILLION)
FIGURE 34 EUROPE HUMAN MICROBIOME MARKET 2019-2027 ($
MILLION)
FIGURE 35 THE UNITED KINGDOM HUMAN MICROBIOME MARKET
2019-2027 ($ MILLION)
FIGURE 36 FRANCE HUMAN MICROBIOME MARKET 2019-2027 ($
MILLION)
FIGURE 37 GERMANY HUMAN MICROBIOME MARKET 2019-2027 ($
MILLION)
FIGURE 38 ITALY HUMAN MICROBIOME MARKET 2019-2027 ($
MILLION)
FIGURE 39 SPAIN HUMAN MICROBIOME MARKET 2019-2027 ($
MILLION)
FIGURE 40 RUSSIA HUMAN MICROBIOME MARKET 2019-2027 ($
MILLION)
FIGURE 41 REST OF EUROPE HUMAN MICROBIOME MARKET
2019-2027 ($ MILLION)
FIGURE 42 ASIA PACIFIC HUMAN MICROBIOME MARKET
2019-2027 ($ MILLION)
FIGURE 43 CHINA HUMAN MICROBIOME MARKET 2019-2027 ($
MILLION)
FIGURE 44 INDIA HUMAN MICROBIOME MARKET 2019-2027 ($
MILLION)
FIGURE 45 JAPAN HUMAN MICROBIOME MARKET 2019-2027 ($
MILLION)
FIGURE 46 SOUTH KOREA HUMAN MICROBIOME MARKET 2019-2027
($ MILLION)
FIGURE 47 AUSTRALIA & NEW ZEALAND HUMAN MICROBIOME
MARKET 2019-2027 ($ MILLION)
FIGURE 48 ASEAN COUNTRIES HUMAN MICROBIOME MARKET
2019-2027 ($ MILLION)
FIGURE 49 REST OF APAC HUMAN MICROBIOME MARKET
2019-2027 ($ MILLION)
FIGURE 50 REST OF WORLD HUMAN MICROBIOME MARKET
2019-2027 ($ MILLION)
FIGURE 51 LATIN AMERICA HUMAN MICROBIOME MARKET
2019-2027 ($ MILLION)
FIGURE 52 BRAZIL HUMAN MICROBIOME MARKET 2019-2027 ($
MILLION)
FIGURE 53 MEXICO HUMAN MICROBIOME MARKET 2019-2027 ($
MILLION)
FIGURE 54 REST OF LATIN AMERICA HUMAN MICROBIOME MARKET
2019-2027 ($ MILLION)
FIGURE 55 MIDDLE EAST & AFRICA HUMAN MICROBIOME
MARKET 2019-2027 ($ MILLION)
FIGURE 56 SAUDI ARABIA HUMAN MICROBIOME MARKET
2019-2027 ($ MILLION)
FIGURE 57 TURKEY HUMAN MICROBIOME MARKET 2019-2027 ($
MILLION)
FIGURE 58 UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET
2019-2027 ($ MILLION)
FIGURE 59 SOUTH AFRICA HUMAN MICROBIOME MARKET
2019-2027 ($ MILLION)
FIGURE 60 REST OF MIDDLE EAST AND AFRICA HUMAN
MICROBIOME MARKET 2019-2027 ($ MILLION)
FIGURE 61 MARKET SHARE ANALYSIS OF GLOBAL HUMAN
MICROBIOME MARKET 2018 (%)